Modification of a Selective NTRK2 Agonist and Confirmation of Activity in a Glaucoma-on-a-Chip Model.
Fatemeh NafianMozhgan Rezaei KanaviMohammad Javad RasaeeBabak Kamali Doust AzadNarsis DaftarianMozhgan Rezaei KanaviPublished in: Journal of ophthalmic & vision research (2024)
The modified peptide studied herein showed improved stability over the original peptide (RNYK) and demonstrated potential for use as a BDNF agonist with neuroprotective properties for treatment of neurodegenerative disorders such as glaucoma.